Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22
BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI”
Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021
Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract
Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned
Proposed Phase 1b/2a clinical trial designed to determine safety and potential efficacy of oral and topical FW-420
BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...
BOCA RATON, Fla., Aug. 18, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma , Inc. (“AzurRx” or the “Company”) ( NASDAQ: AZRX ), a company specializing in the development of targeted, non-systemic therapies...
BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...